Journal of the Korean Association of Oral and Maxillofacial Surgeons : eISSN 2234-5930 / pISSN 2234-7550

Table. 1.

Table. 1.

Patient demographics

No. Sex Age (yr) Drug type Indication Follow-up duration (mo)
1 F 83 Alendronate Osteoporosis 24
2 F 77 Risedronate Osteoporosis 14
3 F 65 Alendronate Osteoporosis 60
4 F 70 Alendronate Osteoporosis 12
5 F 63 Unknown type Osteoporosis 15
6 F 78 Unknown type Osteoporosis 12
7 F 85 Risedronate Osteoporosis 12
8 F 64 Alendronate Osteoporosis 71
9 F 60 Zoledronate Bone tumor 19
10 F 72 Ibandronate Osteoporosis 12
11 F 73 Alendronate Osteoporosis 24
12 F 74 Risedronate Osteoporosis 24
13 F 73 Alendronate Osteoporosis 12
14 F 79 Unknown type Osteoporosis 52
15 F 87 Ibandronate Osteoporosis 12
16 M 65 Alendronate Osteoporosis 14
17 F 75 Ibandronate Osteoporosis 28
18 F 78 Alendronate Osteoporosis 12
19 F 87 Alendronate Osteoporosis 13
20 F 87 Zoledronate Osteoporosis 16
21 F 88 Ibandronate Osteoporosis 12
22 F 70 Risedronate and ibandronate Osteoporosis 24
23 F 69 Ibandronate Osteoporosis 28
24 F 69 Unknown type Osteoporosis 13
25 F 76 Unknown type Osteoporosis 12
26 F 90 Unknown type Osteoporosis 15
27 F 77 Unknown type Osteoporosis 36
28 F 74 Alendronate Osteoporosis 12
29 F 81 Pamidronate Bone tumor 12
30 M 77 Alendronate Osteoporosis 12
31 F 66 Risedronate Osteoporosis 20
32 F 82 Unknown type Osteoporosis 22
33 F 87 Alendronate Osteoporosis 21
34 F 83 Risedronate and denosumab Osteoporosis 12
35 F 70 Risedronate Osteoporosis 17
36 M 41 Zoledronate Bone tumor 28

(F: female, M: male)

J Korean Assoc Oral Maxillofac Surg 2022;48:219~224
https://doi.org/10.5125/jkaoms.2022.48.4.219
© JKAOMS